OQS
MBRX icon

Occudo Quantitative Strategies’s Moleculin Biotech MBRX Stock Holding History

Occudo Quantitative Strategies’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-59
Closed -$41K – 1242
2021
Q4 		$41K Sell
59
-4
-6% -$3.55K ﹤0.01% 1019
2021
Q3 		$70K Sell
63
-15
-19% -$17.5K 0.01% 952
2021
Q2 		$107K Buy
78
+19
+32% +$25.9K 0.02% 786
2021
Q1 		$90K Buy
+59
New +$108K 0.02% 697

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Occudo Quantitative Strategies's MBRX Position: Q1 2022 in Review

Occudo Quantitative Strategies sold out of Moleculin Biotech (MBRX) in Q1 2022, closing a stake of 59 shares — an estimated $41K sold.

Occudo Quantitative Strategies first reported a position in MBRX in Q1 2021 and held it in 4 quarters. The position peaked at $107K in Q2 2021. 22 funds tracked by Wall St. Rank hold MBRX as of Q1 2022.

  • Occudo Quantitative Strategies reported no remaining Moleculin Biotech position as of Q1 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 59 Moleculin Biotech shares in Q1 2022, an estimated $41K.
  • Occudo Quantitative Strategies first reported a position in Moleculin Biotech in Q1 2021 and held it in 4 quarters.
  • Occudo Quantitative Strategies's Moleculin Biotech position peaked at $107K in Q2 2021.
  • 22 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2022, filed 16 May 2022.